CN111728978A - 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 - Google Patents
罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 Download PDFInfo
- Publication number
- CN111728978A CN111728978A CN202010471884.4A CN202010471884A CN111728978A CN 111728978 A CN111728978 A CN 111728978A CN 202010471884 A CN202010471884 A CN 202010471884A CN 111728978 A CN111728978 A CN 111728978A
- Authority
- CN
- China
- Prior art keywords
- mogroside iie
- iie
- food
- mogroside
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WVXIMWMLKSCVTD-JLRHFDOOSA-N Mogroside II-E Chemical compound O([C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WVXIMWMLKSCVTD-JLRHFDOOSA-N 0.000 title claims abstract description 70
- WVXIMWMLKSCVTD-UHFFFAOYSA-N mogroside II E Natural products C1CC2(C)C3CC=C(C(C(OC4C(C(O)C(O)C(CO)O4)O)CC4)(C)C)C4C3(C)C(O)CC2(C)C1C(C)CCC(C(C)(C)O)OC1OC(CO)C(O)C(O)C1O WVXIMWMLKSCVTD-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 30
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 26
- 235000013305 food Nutrition 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002518 antifoaming agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 235000010855 food raising agent Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract description 21
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract description 21
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 13
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract description 12
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 108010018924 Heme Oxygenase-1 Proteins 0.000 abstract description 9
- 102100028006 Heme oxygenase 1 Human genes 0.000 abstract description 9
- 238000001784 detoxification Methods 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 241001409321 Siraitia grosvenorii Species 0.000 abstract description 7
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 abstract description 6
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 abstract description 6
- 108091007960 PI3Ks Proteins 0.000 abstract description 6
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 210000002540 macrophage Anatomy 0.000 description 9
- 229940118019 malondialdehyde Drugs 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001409305 Siraitia Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical class C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- -1 oxygen radicals Chemical class 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 102000018690 Trypsinogen Human genes 0.000 description 2
- 108010027252 Trypsinogen Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004321 EU approved sweetener Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000013234 NASH mouse model Methods 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 238000009012 ROS assay kit Methods 0.000 description 1
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000786103 Steatomys pratensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000031337 regulation of inflammatory response Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于药用天然产物技术领域,具体涉及罗汉果苷IIE在制备抗氧化食品、保健品或药品中的应用。本发明提出了罗汉果苷IIE的新应用,为罗汉果的开发利用提供了新的方向,同时罗汉果苷IIE作为一种食品功能成分,毒副作用较小,可用于抗氧化类食品、保健品和药品的制备,市场前景广阔。本发明研究发现罗汉果苷IIE可以明显地清除细胞组织内ROS,展现了其抗氧化的能力。罗汉果苷IIE可以活化Nrf2/ARE信号通路,激活其下游抗氧化蛋白和Ⅱ相解毒酶:Nrf2、HO‑1和NQO1的表达,罗汉果苷IIE还能抑制PI3K/AKT1信号通路的激活,从而发挥其抗氧化的效果。
Description
技术领域
本发明属于药用天然产物技术领域,具体涉及罗汉果苷IIE在制备抗氧化食品、保健品或药品中的应用。
背景技术
罗汉果(Corsvenor Momordica Fruit)是葫芦科的多年生草本植物,主要分布在我国部分南部地区,具有良药佳果之称,作为民间疗法治疗肺淤血,咽喉痛和便秘数百年。在中国,该植物因其作为甜味水果而备受推崇,广泛应用于药用和食品甜味剂。
罗汉果苷IIE(Mogroside IIE)是一种典型的三萜皂苷,具有苦味,是不到50天青涩罗汉果果实内最主要含有的成分,这一苦味化合物在果实成熟至70天缓慢消失,它同时也是市售甜味剂罗汉果苷V的前体和代谢产物。罗汉果苷V作为一种低热量食品添加剂,由于其具有抗氧化,抗致癌物质和抗炎等特性,成为了最具潜能的化学预防物质之一,也被认为是炽手可热的商业糖代用品,在我国罗汉果苷V作为膳食补充剂可以无限制地添加在各类食品当中。随着食品和医药行业对罗汉果苷V的需求逐渐增加,苦味物质罗汉果苷IIE的潜在价值也变得更加重要,但每年在收获季节的后期,有相当多不适应天气条件的苦果被丢弃。很多年来,虽然人们试图改进栽培和育种方法,以减少生长停滞的影响,但还是有大量的未成熟果实被遗弃,很多罗汉果苷IIE未被利用,同时其生物活性至今鲜有人进行全面的研究和阐述。申请号为2019100276527的发明专利中公开了罗汉果苷IIE在制备胰蛋白酶抑制剂中的应用,其具体公开了罗汉果苷IIE通过抑制腺泡细胞本底的胰蛋白酶活性,并抑制急性胰腺炎诱导剂——雨蛙素对胰蛋白酶原的激活作用,同时其抑制胰蛋白酶原的激活与组织蛋白酶B有关,因此罗汉果苷IIE可用于制备胰蛋白酶抑制剂。
氧化(Oxidation)是一种存在于自然界最为普遍化学反应,是指分子、原子或离子导致的电子损失和电子氧化态的增加,氧化过程中可以产生自由基,从而导致了一系列链式反应,这些反应有可能损伤DNA并导致细胞内脂质和蛋白质的损坏。抗氧化(Antioxidant)是指为了平衡氧化状态,植物和动物体内维持复杂的相互重叠的一种状态。在正常情况的下,人体抗氧化系统是可以清除部分活性氧的,然而,当生物体暴露在烟、酒精、辐射和环境毒素等下的时候,体内受到刺激产生过度的活性氧簇,破坏氧化和抗氧化之间的平衡,并导致生物体产生一些慢性或退行性疾病。
发明内容
针对目前罗汉果苷IIE利用率较低的技术问题,本发明的目的是提供一种罗汉果苷IIE在制备抗氧化食品、保健品或药品中的新应用,经本申请发明人长期研究发现,罗汉果苷IIE能够清除细胞内ROS,通过调控PI3K/AKT1-Nrf2/ARE信号通道来抵抗氧化应激,并增强抗氧化蛋白的表达,从而发挥其抗氧化作用。
为了实现上述目的,本发明采用如下技术方案:
本发明提供一种罗汉果苷IIE在制备抗氧化食品、保健品或药品中的应用。
所述罗汉果苷IIE的结构式为:
进一步地,所述食品或保健品中包括罗汉果苷IIE作为活性成分。
进一步地,所述食品或保健品中还包括食品添加剂或食品原料。
进一步地,所述食品添加剂为防腐剂、着色剂、甜味剂、矫味剂、膨松剂、增稠剂、乳化剂、消泡剂的其中一种或多种。
进一步地,所述药品中包括罗汉果苷IIE作为活性成分。
进一步地,所述药品中还包括药学上可接受的辅料。
进一步地,所述辅料为填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质的其中一种或多种。
进一步地,所述药品的剂型为胶囊剂、片剂、颗粒剂、散剂、口服液、丸剂的其中一种。
与现有技术相比,本发明具有如下有益效果:
本发明提出了罗汉果苷IIE的新应用,为罗汉果的开发利用提供了新的方向,同时罗汉果苷IIE作为一种食品功能成分,毒副作用较小,可用于抗氧化类食品、保健品或药品的制备,市场前景广阔。本发明研究发现罗汉果苷IIE可以明显地清除细胞组织内ROS,展现了其抗氧化的能力。罗汉果苷IIE可以活化Nrf2/ARE信号通路,激活其下游抗氧化蛋白和Ⅱ相解毒酶:Nrf2、HO-1和NQO1的表达,罗汉果苷IIE还能抑制PI3K/AKT1信号通路的激活,从而发挥其抗氧化的效果。
附图说明
图1为罗汉果苷IIE对RAW264.7细胞存活的影响。
图2为倒置荧光显微镜观察巨噬细胞内ROS的变化情况。
图3为荧光酶标仪测定各组ROS的产生情况。
图4为罗汉果苷IIE对Nrf2/ARE信号通路相关蛋白影响情况。
图5为罗汉果苷IIE对AKT磷酸化水平的影响。
图6为罗汉果苷IIE对小鼠肝脏MDA浓度(高脂小鼠模型对照)的影响。
图7为罗汉果苷IIE对小鼠谷胱甘肽过氧化物酶(GSH-Px)水平的影响。
图8为罗汉果苷IIE对小鼠超氧化物歧化酶(SOD)水平的影响。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下实施例中罗汉果苷IIE来源于湖南绿蔓生物科技股份有限公司,通过高效液相色谱纯化使其纯度≥98%。小鼠巨噬细胞RAW 264.7来自于美国ATCC模式细胞中心,ROS测定使用的是碧云天活性氧测定试剂盒,其他所使用的材料均可自常规途径购买得到。
应用例
本应用例提供一种罗汉果苷IIE在制备抗氧化食品、保健品或药品中的应用。
所述食品或保健品中还包括食品添加剂或食品原料,所述食品添加剂为防腐剂、着色剂、甜味剂、矫味剂、膨松剂、增稠剂、乳化剂、消泡剂的其中一种或多种。
所述药品中还包括药学上可接受的辅料,所述辅料为填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质的其中一种或多种;所述药品的剂型可为胶囊剂、片剂、颗粒剂、散剂、口服液、丸剂或注射剂等。
实施例1 MTT法检测罗汉果苷IIE对RAW264.7细胞存活的影响
在美国ATCC模式细胞中心购买小鼠巨噬细胞RAW264.7。培养在含有10%胎牛血清(FBS)的DMEM培养基中,培养箱环境为恒定37℃和充斥着稳定的5%CO2气体。经过细胞复苏、细胞培养、细胞传代和细胞计数后,使用MTT比色法进行细胞毒性测定,检测罗汉果苷IIE对RAW264.7细胞存活的影响。具体测定步骤如下:
准备好96孔板,收集状态好的细胞,铺板使待测细胞调密度至4×104/孔,边缘孔培养基填充,确认细胞生长状态良好后即可加入浓度梯度的待测药物,设置好合适的梯度,并设置复孔,放入培养箱培养16-48小时。移出96孔板中的旧培养基,替换为新鲜的无血清培养基,放置于培养箱中37℃预培养2.5小时。加入罗汉果苷IIE于96孔板中,37℃培养箱继续培养2小时培养过后每孔加入20ulMTT溶液(0.5%MTT),继续培养,等待测样品与MTT反应完成,终止培养,拿出96孔板,倾斜孔板以便吸除孔内培养液,把150ul二甲基亚砜分别加在每个孔内,低速摇动10min使结晶物完全溶解。在酶联免疫检测仪OD490nm处测定每个孔的吸光度。
本实施例设置了空白、80μM、160μM、320μM和640μM五个梯度来检测罗汉果苷IIE对细胞存活率的影响情况。分别在3h、6h、9h和12h的时候检测其吸光度,检测结果如图1所示,检测到的吸光度越高代表细胞增殖越快,具有活力,样品毒性也就越小,如下图所示当样品浓度在0-160mg/ml的时候,吸光度随着浓度的上升而增加,而在160μM之后,吸光度随之下降,且这一结果不受时间的影响。说明在样品浓度为160μM时样品有促进细胞增殖提高细胞活力的作用,而之后随着样品浓度的增加细胞的生长会受到阻碍。同时平均间隔三个小时进行了测定,发现当处理时间为12h时,变化趋势最明显,样品效果也最好。因此以下实施例中将样品浓度控制在320μM之内进行,并且于巨噬细胞处理时间为12个小时时收取其蛋白进行实验。
实施例2 ROS活性检测
用脂多糖LPS诱导细胞时,会让细胞内充斥着ROS,导致自由基堆积于细胞或组织内部,而过度氧化有可能损伤DNA并导致细胞内脂质和蛋白质的损坏,从而加速细胞的衰老,激发炎症介质的形成,引发一系列的疾病。因此本实施例先采用LPS刺激细胞,构建细胞氧化损伤模型,再检测罗汉果苷IIE在小鼠巨噬细胞模型中的抗氧化效果。
本实施例采用碧云天活性氧测定试剂盒测定ROS,试剂盒内包括DCFH-DA和活性氧阳性对照。用LPS和罗汉果苷IIE处理细胞,分为空白组、LPS(40μg/mL)组、LPS+罗汉果苷IIE(20μM)组、LPS+罗汉果苷IIE(40μM)组、LPS+罗汉果苷IIE(80μM)组、LPS+罗汉果苷IIE(160μM)组共六个组,每个浓度3个复孔,最后采用荧光显微镜和荧光酶标仪检测细胞内活性氧的水平变化。结果如图2和图3所示。
图2用DCFH-DA探针检测罗汉果IIE对LPS刺激的RAW264.7巨噬细胞内活性氧的变化情况。图2中,在LPS的刺激下,巨噬细胞中的ROS有显著性增加的效果,用罗汉果苷IIE治疗后,细胞内ROS明显减少,且增加的量越多抑制效果越明显,当浓度添加至80μM和160μM时,细胞内几乎不可见活性氧的产生。
图3对巨噬细胞内发出的荧光进行了定量测定,用荧光酶标仪检测的结果显示在罗汉果IIE浓度为20μM和40μM时,能抑制细胞内ROS的产生(p<0.05);样品浓度在80μM时能显著性地降低荧光的产生(p<0.01);当添加至160μM时,罗汉果IIE能完全抑制细胞内ROS的水平(p<0.001)且结果呈量-效依赖关系。
由上述结果可得知,罗汉果IIE能降低由LPS诱导的巨噬细胞内ROS的产生,两种检测方法都显示出当罗汉果IIE含量为160μM,能完全抑制细胞内ROS的水平,且当罗汉果IIE的添加量越多抑制效果越明显,说明罗汉果苷IIE通过清除了细胞组织内ROS,展现了其抗氧化的能力。
实施例3罗汉果苷IIE对Nrf2/ARE信号通路的影响
Nrf2作为重要的核转录因子,可调节抗氧化蛋白的表达,从而防止由炎症引发的氧化反应。当Nrf2被激活时,会进入核内与ARE相结合,启动其下游一系列的Ⅱ相解毒酶和抗氧化基因一同清除细胞内的过量的活性氧。HO-1是一种保护酶和限速酶,在正常情况下表达不明显,而当生物体内产生氧化应激激活Nrf2通路时,HO-1为了抵抗外界刺激而表达瞬间上升,所以可通过测定HO-1来判断是否激活Nrf2/ARE信号通路。NQO1则是一种胞内酶,可以催化多种化合物的还原。其主要生理作用是减少细胞中自由基和异生素的解毒。NQO1是Nrf2/ARE信号通路中的Ⅱ相解毒酶,Nrf2可以调控NQO1的表达。
因此在本实施例中通过检测Nrf2、HO-1和NQO1的表达,来测定罗汉苷果IIE对Nrf2/ARE信号通路的影响情况。测定结果如图4所示。
图4中免疫印迹条带显示,在脂多糖LPS的刺激下,Nrf2/ARE信号通路关键蛋白Nrf2和HO-1都发生了表达,这说明在稳态平衡条件下,这些抗氧化相关蛋白表达量较少,氧化应激产生时,其表达量上升。当添加了罗汉果苷IIE样品之后,这三种抗氧化蛋白和II相解毒酶的表达都出现了增加。灰度值分析发现在罗汉果苷IIE添加量不多时,HO-1表达并不明显,当样品浓度增加到160μM时,其表达量明显(p<0.05);Nrf2的表达则很剧烈,样品浓度为20μM和40μM时,其表达量显著性增加(p<0.01),80μM和160μM时细胞内Nrf2较LPS对照组相比极显著(p<0.001);NQO1在较低样品浓度时上升趋势不明显,当添加量达到80μM和160μM时,其表达量出现明显的增加。
以上可知,Nrf2/ARE信号通路主要蛋白和下游解毒酶:Nrf2、HO-1和NQO1的表达均有增加的趋势。结果说明罗汉果苷IIE促使了Nrf2/ARE信号通路的活化,诱发了抗氧化蛋白和解毒酶,共同抵抗氧化应激,从而发挥了其抗氧化的效果。
实施例4罗汉果苷IIE对PI3K/AKT1信号通路的影响
PI3K/AKT1信号通路在活性氧的产生和解毒过程中有重要的作用,AKT1也参与了炎症反应的调节。所以通过测定AKT1,可以进一步验证罗汉果IIE的抗氧化作用。
如图5所示,细胞培养(1×106个细胞)并用罗汉果苷IIE(12.5-50μM)处理,检测总蛋白激酶和磷酸化蛋白激酶,用相应的抗体进行western blot实验。在LPS的刺激下,磷酸化AKT1被诱导,细胞内总AKT1没有变化,当罗汉果苷IIE加入,AKT1的磷酸化水平呈剂量依赖性被抑制,在样品添加量为25μM时,抑制效果明显(p<0.05);罗汉果苷IIE浓度为50μM的时候,AKT1磷酸化水平显著性下降(p<0.01)。结果显示,罗汉果苷IIE通过调控AKT1来影响PI3K/AKT1信号通路的激活,从而调节细胞内氧化应激,实现抗氧化和抗炎的效果。
实施例5罗汉果苷ⅡE对小鼠机体抗氧化指标的改善作用
选取60只4周龄体重接近(20±1.7g),生长状况良好的C57BL/6雄性小鼠,将它们饲养至恒温培养箱中,实验期间,小鼠自由摄食、饮水,室内温度23±2℃,相对湿度55-60%,12h白天/12h黑暗周期,室内通风良好并按照饲料配方和营养成分表(见表1)提供食物。每天观察小鼠的活动情况以及精神状态,每周称量两次体重。生物体内,自由基作用于脂质发生过氧化反应,氧化最终产物为丙二醛,会引起蛋白质、核酸等生命大分子的交联聚合,且具有细胞毒性。机体通过酶系统与非酶系统产生氧自由基,后者能攻击生物膜中的多不饱和脂肪酸,引发脂质过氧化作用,并因此形成脂质过氧化酸。脂质过氧化作用不仅把活性氧转化成活性化学剂,即非自由基性的脂类分解产物,而且通过链式或链式支链反应,放大活性氧的作用。
(1)实验对象处理
适应性喂养一周后,将60只小鼠根据体重随机分为5个处理组,每组12只进行不同条件的喂养。组1(standard diet,STD),小鼠给予标准日粮;组2(high fat diet,HFD),小鼠给予高脂肪日粮;组3(HFD+100mg/kg BW MIIE,HFD+L-MFE),小鼠摄入高脂肪日粮并灌胃低剂量的MIIE(100mg/kg BW).组4(HFD+200mg/kg BW MIIE,HFD+H-MFE),小鼠接受高脂肪日粮和高剂量MIIE(200mg/kg食物)的灌胃.组5(STD+200mg/kg BW MIIE,STD+H-MFE),小鼠接受标准食物和高剂量的PMR(200mg/kg食物)。
表1饲粮组成及营养水平
Table 4-1Composition of the experiment diets and nutrition level(g/100g diet)
高脂肪模型是最常用的氧化应激模型,便于创造和和人体接近的环境,小鼠和大鼠实验一般选择脂肪含量10-50%之间的高脂肪饲料,同时补充0.5%-2%的胆固醇4-6周内可以诱导小鼠发生氧化应激状态。
将称量得到的小鼠体重数据进行统计学分析,当出现显著性差异时即可判定高脂小鼠模型建立。
(2)小鼠血浆与组织采集
经过8个星期的干预,将小鼠空腹12小时后,乙醚麻醉,摘眼睛取血至10mL塑料离心管。静置15分钟后,4℃,4000rpm离心15分钟。将分离得到的血清放置于-20℃冰箱中保存,以备后续各项指标的检测。进一步将小鼠处死,体表用75%乙醇擦拭消毒,打开腹腔,将肝脏、脾脏、肾等器官组织迅速取出后用滤纸吸掉多余水分后称重并记录其鲜重,然后经锡箔纸包裹后置于-80℃冰箱中保存。
器官指数=各个器官鲜重/实验结束时大鼠体重
(3)小鼠抗氧化指标检测及结果分析
参照相关试剂盒说明书分别检测各组小鼠血清中丙二醛(Maleic dialdehyde,MDA)的含量以及超氧化物歧化酶(Superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-Px)的活力。本专利选取其中最具代表性的小鼠血清中丙二醛(Maleic dialdehyde,MDA)的含量检测过程,进行详细说明。
C57BL/6小鼠连续干预8周后禁食12h,将小鼠断髓处死、解剖,取一小块肝脏组织,立即放入到4%的多聚甲醛固定液中。
取肝脏组织,按生理盐水以1:9(w/v)的比例,在玻璃匀浆管中制成匀浆。过氧化值测定方法如下:
①将匀浆静置15min后,取上清液备用。在水浴加热锅中,水浴温度70℃加热10分钟。使用离心机在室温环境中,以2000rpm离心5分钟。取其上层清液即可用于过氧化值测定。
②工作液的配制:取4ml试剂R1与1ml试剂R2混匀,比例为4:1,立即使用(在4℃环境中保存,保存时间小于24h,如若变色则不能的使用)。
③标准品的配制:用蒸馏水将4mM的甘油三酯标准品倍比稀释成1000、500、250、125、62.5、31.25、15.625、7.8125μmol/L液体,设置0浓度对照管。
④选用96孔板,按照下表加样。
空白管 | 校准管 | 样品管 | |
工作液 | 190微升 | 190微升 | 190微升 |
蒸馏水 | 10微升 | 无 | 无 |
校准 | 无 | 10微升 | 无 |
样品 | 无 | 无 | 10微升 |
取上清液200μL加入96孔板中,随后在酶标仪波长532nm测定吸光度。绘制标准曲线并计算相应MDA(丙二醛)浓度。
罗汉果苷ⅡE干预NASH模型小鼠8周后,结合HFD组和STD组,我们发现高脂饮食导致小鼠MDA水平显著增加(P<0.01)。随着罗汉果ⅡE的浓度增高,肝匀浆MDA水平呈梯度下降趋势,各数据差异有统计学意义(P<0.05)。具体结果如图6所示。
图7为罗汉果苷IIE对小鼠谷胱甘肽过氧化物酶(GSH-Px)水平的影响。
图8为罗汉果苷IIE对小鼠超氧化物歧化酶(SOD)水平的影响。
综上所述,罗汉果苷ⅡE具有良好的体内抗氧化效果。
Claims (9)
1.罗汉果苷IIE在制备抗氧化食品、保健品或药品中的应用。
3.根据权利要求1所述的应用,其特征在于,所述食品或保健品中包括罗汉果苷IIE作为活性成分。
4.根据权利要求3所述的应用,其特征在于,所述食品或保健品中还包括食品添加剂或食品原料。
5.根据权利要求4所述的应用,其特征在于,所述食品添加剂为防腐剂、着色剂、甜味剂、矫味剂、膨松剂、增稠剂、乳化剂、消泡剂的其中一种或多种。
6.根据权利要求1所述的应用,其特征在于,所述药品中包括罗汉果苷IIE作为活性成分。
7.根据权利要求6所述的应用,其特征在于,所述药品中还包括药学上可接受的辅料。
8.根据权利要求7所述的应用,其特征在于,所述辅料为填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质的其中一种或多种。
9.根据权利要求6或7所述的应用,其特征在于,所述药品的剂型为胶囊剂、片剂、颗粒剂、散剂、口服液、丸剂的其中一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010471884.4A CN111728978A (zh) | 2020-05-29 | 2020-05-29 | 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010471884.4A CN111728978A (zh) | 2020-05-29 | 2020-05-29 | 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111728978A true CN111728978A (zh) | 2020-10-02 |
Family
ID=72647899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010471884.4A Pending CN111728978A (zh) | 2020-05-29 | 2020-05-29 | 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111728978A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103613629A (zh) * | 2013-11-29 | 2014-03-05 | 广西壮族自治区中国科学院广西植物研究所 | 从罗汉果中制备高纯度罗汉果苷iie的方法 |
-
2020
- 2020-05-29 CN CN202010471884.4A patent/CN111728978A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103613629A (zh) * | 2013-11-29 | 2014-03-05 | 广西壮族自治区中国科学院广西植物研究所 | 从罗汉果中制备高纯度罗汉果苷iie的方法 |
Non-Patent Citations (2)
Title |
---|
WANG L.等: "Cucurbitane Glycosides Derived from Mogroside II E : Structure-Taste Relationships, Antioxidant Activity, and Acute Toxicity" * |
朱慧玲: "罗汉果皂甙类化合物的分离、纯化及其抗氧化活性研究" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peteliuk et al. | Natural sweetener Stevia rebaudiana: Functionalities, health benefits and potential risks | |
El Batran et al. | Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats | |
Aydos et al. | Antiproliferative, apoptotic and antioxidant activities of wheatgrass (Triticum aestivum L.) extract on CML (K562) cell line | |
Ramarathnam et al. | The contribution of plant food antioxidants to human health | |
JP6335508B2 (ja) | 成長ホルモン分泌促進剤 | |
KR20200120465A (ko) | 숙취해소에 뛰어나며 알코올에 의한 간 손상을 예방 또는 치료용 조성물 | |
KR101930483B1 (ko) | 발효 청미래덩굴 잎 및 이의 추출물 | |
EP2251024A1 (en) | Plant-origin drug for preventing or improving hyperuricemia | |
KR20200031805A (ko) | 천마와 굼벵이를 유효성분으로 함유하는 간질환의 예방 또는 개선용 건강식품 조성물 | |
SHARANGİ et al. | Stevia: Medicinal Miracles and therapeutic magic | |
KR101965061B1 (ko) | 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
Lieshchova et al. | Effect of Salvia officinalis and S. sclarea on rats with a high-fat hypercaloric diet | |
KR101209574B1 (ko) | 이고들빼기로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
KR20120044807A (ko) | 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물 | |
KR20180098888A (ko) | 땅콩새싹 추출물을 유효성분으로 포함하는 면역력 증강용 조성물 | |
CN111728978A (zh) | 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 | |
US20210212928A1 (en) | Sirtuin 1 activation agent and skin cosmetic for activating sirtuin 1 | |
KR101935861B1 (ko) | 숙취해소 및 간 기능 개선용 건강 기능성 식품 조성물 및 이의 제조 방법 | |
Josepha et al. | Antihyperglycaemic and antioxidant effects of Adenia lobata Engl (Passifloraceae) in streptozotocin-induced diabetic rats | |
KR101999383B1 (ko) | 매생이 추출물을 유효성분으로 포함하는 알코올성 간질환의 개선, 예방 또는 치료용 약제학적 조성물 | |
KR101062003B1 (ko) | 사방오리나무 추출물 또는 그로부터 분리된 화합물을 유효성분으로 하는 당뇨병 예방 및 치료용 조성물 | |
KR100895500B1 (ko) | 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및치료용 조성물 | |
KR20210078693A (ko) | 개똥쑥 추출물을 포함하는 간기능 개선효능을 갖는 조성물 | |
CN105597083B (zh) | 一种对肝肾有辅助保护作用的保健食品及其制备方法 | |
KR102621205B1 (ko) | 옻 추출물, 장수버섯 추출물 및 고정차 추출물을 포함하는 항산화 및 항염증 효과를 가지는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201002 |
|
RJ01 | Rejection of invention patent application after publication |